Paroxysmal supraventricular tachycardia, or PSVT, is a type of abnormally fast heart rhythm that starts suddenly, runs at roughly 150 to 250 beats per minute, and then stops just as abruptly. It affects somewhere between 168 and 332 people per 100,000, making it one of the more common heart rhythm disturbances that sends people to an emergency room.1JAMA. Diagnosis and Management of Paroxysmal Supraventricular Tachycardia Despite how alarming an episode feels, PSVT is rarely life-threatening, though it can significantly disrupt daily life and is frequently mistaken for something else entirely.
What Is Happening Inside the Heart
During a PSVT episode, an electrical signal gets trapped in a loop somewhere in or near the upper chambers of the heart, circling around and firing the heartbeat far faster than normal. The “paroxysmal” part simply means the episodes come and go without warning. There are a few distinct electrical circuits that can cause this, and which one you have matters for treatment.
The most common type, accounting for roughly 56% of cases in a large electrophysiology study, involves a short circuit within the AV node itself, the small relay station between the upper and lower chambers. This is called AV nodal reentrant tachycardia, or AVNRT. An electrical impulse travels down one pathway through the node and loops back up through a second pathway, circling endlessly until something interrupts it.2PubMed. Influence of age and gender on the mechanism of supraventricular tachycardia The second most common type, responsible for about 27% of cases in that same study, uses an extra electrical connection between the upper and lower chambers called an accessory pathway. This is AV reentrant tachycardia, or AVRT, and it is the mechanism behind Wolff-Parkinson-White syndrome. A smaller group, around 17%, have atrial tachycardia, where the rapid firing originates in the atrial tissue itself.
These subtypes don’t affect people equally. AVRT tends to appear in younger patients and is slightly more common in men, while AVNRT and atrial tachycardia become more prevalent with age and are more common in women.3PubMed. Influence of age and gender on the mechanism of supraventricular tachycardia This is one reason why a first PSVT episode in a teenager and a first episode in a 65-year-old may involve different underlying circuits and call for somewhat different management strategies.
What an Episode Feels Like
The hallmark symptom is a sudden pounding or racing sensation in the chest. In one study examining how patients present, palpitations were reported by 84% of people during episodes, followed by chest pain in 47%, shortness of breath in 38%, and fainting in about a quarter of patients.4PubMed Central. Clinical presentation of paroxysmal supraventricular tachycardia: evaluation of usual and unusual symptoms Lightheadedness and sweating are also common. The episode can last seconds, minutes, or occasionally hours. Some people describe a fluttering sensation in the neck, caused by the atria contracting against closed heart valves.
Fainting during PSVT is less common than you might expect given how fast the heart is going. When it does happen, it probably reflects an overreaction of the body’s blood-pressure regulation system rather than the heart rate alone. The autonomic nervous system, responsible for keeping blood pressure steady, can sometimes respond poorly to the hemodynamic stress of the rapid heartbeat, leading to a drop in blood flow to the brain.5PubMed Central. Syncope associated with supraventricular tachycardia: Diagnostic role of implantable loop recorders
The Panic Disorder Problem
One of the most consequential things about PSVT is how often it gets misdiagnosed as a psychiatric condition. The overlap with panic attacks is almost uncanny: racing heart, chest tightness, shortness of breath, dizziness, tingling, and a sense of impending doom. A PSVT episode can trigger genuine anxiety, and the anxiety itself can produce many of the same physical sensations, creating a feedback loop that makes the two conditions nearly impossible to distinguish on symptoms alone.6PubMed Central. Panic attacks and supraventricular tachycardias: the chicken or the egg?
A study of 59 patients who were eventually diagnosed with PSVT found that 67% of them had previously met the formal criteria for panic disorder, and over half had been told by a doctor that their symptoms were caused by panic, anxiety, or stress before anyone caught the real rhythm problem.7JAMA Internal Medicine. Unrecognized Paroxysmal Supraventricular Tachycardia: Potential for Misdiagnosis as Panic Disorder The central difficulty is that PSVT episodes often stop before the patient reaches medical attention, so there is nothing abnormal on the ECG by the time a doctor sees them. This makes it easy to chalk up the symptoms to anxiety. If you have episodes of sudden, rapid heartbeat that start and stop sharply rather than building gradually, push for cardiac monitoring. A continuous event monitor worn for days or weeks can catch what a single ECG visit misses.
How to Stop an Episode at Home
When PSVT strikes, the first-line approach is a physical technique that stimulates the vagus nerve, which can interrupt the electrical loop. The classic version involves bearing down hard as if straining on the toilet (a Valsalva maneuver), but a modified approach works considerably better. In the modified version, you strain while sitting at a 45-degree angle, then immediately lie flat and have someone lift your legs to about 45 degrees for 15 seconds. A meta-analysis found the modified technique was roughly twice as likely to convert the rhythm back to normal compared with the standard strain-and-release approach.8PubMed Central. Efficacy and safety of modified Valsalva maneuver for treatment of paroxysmal supraventricular tachycardia: a meta-analysis
Newer research has combined the modified Valsalva with a reverse Valsalva (a technique involving forceful inhalation against resistance, like sucking hard through a narrow straw). A retrospective study found a first-attempt success rate of about 59% with the combined technique compared with 35% for the modified Valsalva alone, and the cumulative success rate after up to three attempts reached roughly 81%, cutting the need for medication nearly in half.9Scientific Reports. Efficacy of a combined reverse and modified Valsalva maneuver for the cardioversion of paroxysmal supraventricular tachycardia: a retrospective cohort study Other vagal tricks people try, such as splashing ice-cold water on the face or briefly immersing the face in cold water, work on the same principle by stimulating the diving reflex, though they tend to be less reliable than a well-executed Valsalva.
What Happens in the Emergency Room
If vagal maneuvers fail, the next step in an ER is typically intravenous adenosine, a naturally occurring molecule that briefly blocks conduction through the AV node and can snap the heart out of its loop. The effect is dramatic: the heart may pause for a few seconds before restarting in a normal rhythm. It works fast, converting most episodes within about 20 to 45 seconds.10PubMed. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia The catch is that adenosine wears off almost instantly, and the tachycardia comes back in a meaningful number of patients. In one early ER study, 57% of patients who initially converted had the rhythm recur within five minutes, requiring additional medication to keep the heart in normal rhythm.11PubMed. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia
Dosing matters quite a bit. When adenosine was given at a higher weight-based dose, the first-dose success rate reached about 93%, compared with roughly 60% at lower doses, and without a meaningful increase in side effects.12PubMed Central. Improved First Dose Conversion of Supraventricular Tachycardia Using Weight-Based Adenosine This has led some emergency physicians to favor weight-based dosing over the traditional fixed-dose protocol. The experience of receiving adenosine can be unpleasant, with a brief feeling of chest pressure, flushing, or the alarming sensation that the heart has stopped, but these effects vanish within seconds.
When adenosine converts the rhythm but episodes keep recurring shortly afterward, giving an oral calcium channel blocker like verapamil after the adenosine can help prevent that bounce-back. One randomized trial showed a significantly lower recurrence rate in patients who received oral verapamil alongside adenosine compared with those who received adenosine alone.13PubMed. Oral verapamil in paroxysmal supraventricular tachycardia recurrence control: a randomized clinical trial
Longer-Term Medication Options
For people who have frequent episodes but want to avoid or delay a procedure, daily medication can reduce how often PSVT returns. Calcium channel blockers like verapamil and beta-blockers like metoprolol are the mainstays. They work by slowing conduction through the AV node, making it harder for the reentrant loop to sustain itself. For patients who break through first-line drugs, antiarrhythmics like flecainide can be more effective at preventing attacks. A randomized trial comparing flecainide with verapamil found that 30% of flecainide patients went the entire study period without a single symptomatic episode, compared with 13% on verapamil, though both drugs substantially reduced attack frequency.14PubMed. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia
Some patients use a “pill-in-the-pocket” approach, carrying a single dose of a fast-acting medication to take only when an episode starts, rather than taking a daily drug. This strategy is particularly appealing for people with infrequent but disruptive episodes who don’t want the side effects of daily therapy. Whether to pursue daily medication, pill-in-the-pocket, or ablation depends heavily on how often episodes occur, how well they respond to vagal maneuvers, and how much they interfere with your life.
Catheter Ablation as a Cure
For many people with PSVT, catheter ablation offers a real shot at a permanent fix. The procedure involves threading thin wires through a vein in the groin up to the heart, mapping the abnormal electrical circuit, and then destroying it with a small burst of energy. Success rates for ablation of AVNRT and AVRT are high, generally above 95%, with a low risk of serious complications. In terms of cost and quality of life, a modeling study found that for patients with monthly episodes, ablation was both more effective and less expensive over a lifetime than long-term drug therapy, improving quality-adjusted life expectancy by about three years and saving roughly $28,000 in lifetime medical costs compared with chronic medication.15PubMed. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia
Traditionally, ablation has used radiofrequency energy, which heats and destroys the tissue. A newer technology, pulsed electric field ablation, creates tiny pores in the target cells using rapid electrical pulses rather than heat, which may reduce the risk of damaging surrounding structures. Early comparative data suggests that pulsed electric field ablation produces safety and efficacy outcomes similar to radiofrequency for PSVT.16PubMed. Pulsed electric field and radiofrequency ablation for paroxysmal supraventricular tachycardia: a propensity score-matched comparison (PFA-SVT study) One study of healthcare utilization after ablation found significant decreases in medication use, though overall spending, ER visits, and diagnostic testing rates were similar to those of matched patients who did not undergo the procedure.17International Journal of Cardiology. Catheter ablation for supraventricular tachycardia and health resource utilization and expenditures: A propensity-matched cohort study That may partly reflect continued monitoring and follow-up after ablation rather than treatment failure.
PSVT in Pregnancy
Pregnancy creates the perfect storm for PSVT. Blood volume rises, resting heart rate increases, and hormonal changes alter the electrical properties of heart tissue. Women who have never had an arrhythmia can develop PSVT for the first time during pregnancy, and those with a known history often find that episodes become more frequent or harder to control.
Treatment options are somewhat restricted by trimester. Intravenous adenosine appears safe and effective in all three trimesters, including during labor, and has not been associated with adverse effects on the fetus in the published case literature.18PubMed. Adenosine use in pregnant women with supraventricular tachycardia Other commonly used drugs like atenolol and verapamil can be used in the second and third trimesters but are contraindicated in the first trimester due to potential effects on fetal development. For hemodynamically unstable or drug-resistant episodes, electrical cardioversion can be performed safely in all trimesters, though in the third trimester it carries a small risk of triggering preterm labor.19PubMed Central. Supraventricular Tachycardia in Pregnancy: Gestational and Labor Differences in Treatment Vagal maneuvers remain the safest first step at any stage of pregnancy.
PSVT in Children
In pediatric patients, PSVT has a distinctive natural history that differs sharply from the adult pattern. About half of children with the condition have their first episode in the first year of life, often in the first few months. The encouraging news for parents is that more than 90% of these infants will have the arrhythmia resolve on its own by age one.20JAMA Pediatrics. Supraventricular Tachycardia However, up to a third of those infants will see the arrhythmia come back later in childhood, at an average age of around eight. In contrast, children who are first diagnosed after infancy have a much lower chance of spontaneous resolution, with only about 15% growing out of it.21JAMA Pediatrics. Supraventricular Tachycardia This split matters clinically because it shapes how aggressively doctors pursue treatment versus watchful waiting.
AVRT with an accessory pathway is proportionally more common in children than in adults, partly because the accessory pathway is often present from birth. Some of these children have Wolff-Parkinson-White pattern visible on a resting ECG even when they are not having an episode, which can help with diagnosis. Most pediatric cardiologists prefer to manage younger children with medication until they are old enough for catheter ablation to be performed with lower risk, typically after age five or so, though the exact timing is individualized.
Wolff-Parkinson-White and the Genetics of Accessory Pathways
Most PSVT occurs in structurally normal hearts with no clear family history. Wolff-Parkinson-White syndrome is a partial exception. While most cases appear sporadically, a familial form has been linked to mutations in the PRKAG2 gene, which encodes part of an enzyme involved in cellular energy metabolism. Affected family members in the original studies had both the accessory pathway and associated heart-muscle thickening and conduction abnormalities.22PubMed. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome A larger genetic study of over 150 WPW patients found a PRKAG2 variant in less than 1% of cases and identified new variants in other genes linked to arrhythmia and heart-muscle disorders, including ANK2, PITX2, and PRDM16.23PubMed Central. Wolff-Parkinson-White syndrome: De novo variants and evidence for mutational burden in genes associated with atrial fibrillation These findings suggest that the genetic architecture behind WPW is complex and overlaps with pathways involved in atrial fibrillation, but for the vast majority of people with PSVT, there is no identifiable genetic cause and no reason to pursue genetic testing.
Etripamil and the Future of At-Home Treatment
One of the biggest frustrations for people living with PSVT is the gap between what you can do at home (vagal maneuvers, which don’t always work) and what requires a trip to the ER (intravenous drugs). A medication called etripamil, delivered as a nasal spray, is designed to close that gap. It is a short-acting calcium channel blocker similar to verapamil that is absorbed through the nasal lining and reaches the heart quickly.24PubMed Central. Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia
The idea is that you would carry the spray and self-administer it when an episode starts, potentially ending the tachycardia within minutes without needing an ER visit. An extension study following patients who used etripamil for repeated episodes over a longer period found that it was well tolerated for self-treatment without medical supervision.25PubMed Central. Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study A systematic review and meta-analysis of randomized trials concluded that etripamil nasal spray shows promise for unsupervised termination of PSVT but noted that additional trials are still needed before it can be broadly endorsed.26PubMed Central. The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials If etripamil reaches widespread clinical use, it could reshape how patients and clinicians think about PSVT management, turning what currently requires an ambulance call into something handled at your kitchen table.
Getting the ECG at the Right Time
The central diagnostic challenge with PSVT is that the heart is usually behaving perfectly normally by the time you sit down in a doctor’s office. A standard 12-lead ECG will be completely unremarkable between episodes for most patients with AVNRT or atrial tachycardia. Patients with an accessory pathway may show a telltale pre-excitation pattern on a resting ECG, but even that is absent in people with “concealed” pathways that only conduct in one direction.
This is why ambulatory monitoring is so important. Event recorders, loop recorders, and increasingly consumer wearable devices can capture the rhythm during symptoms. Smartwatches with optical heart-rate sensors have been reported to detect supraventricular tachycardia, though major cardiology societies have not endorsed them as diagnostic tools.27PubMed Central. Smartwatch detection of ventricular tachycardia: Case series Still, a watch recording showing a sudden jump from 70 to 190 beats per minute with an equally sudden return to baseline can be enormously useful in a clinical conversation. It gives your doctor something concrete to work with, even if the tracings are not medical-grade. For anyone who suspects PSVT, starting to log episodes with whatever technology is available, even just noting the time and duration, can speed the journey to a proper diagnosis.
When the ECG does capture a wide QRS complex during tachycardia, distinguishing PSVT with aberrant conduction from a more dangerous ventricular tachycardia becomes critical. Features like the width of the QRS complex, the frontal axis of the electrical signal, and the presence of certain patterns can help differentiate the two, but this distinction remains one of the trickier calls in emergency cardiology.28PubMed. Wide QRS complex tachycardia: ECG differential diagnosis The default in an ER, reasonably, is to treat any wide-complex tachycardia as ventricular in origin until proven otherwise, because making the wrong call in that direction is far more dangerous.